Blood transcriptomic signatures of vascular risk in Alzheimer’s disease

by Clinical Neuropsychologist Online | Sunday, October 25, 2026 | Dementia

Abstract INTRODUCTION Lifestyle and environmental factors contributing to cardiovascular risk are components of the exposome, yet molecular signatures associated with cumulative cardiovascular risk in Alzheimer’s disease (AD) remain incompletely understood....

Vascular drivers of cerebrospinal fluid movement and enlarged perivascular spaces

by Clinical Neuropsychologist Online | Sunday, October 25, 2026 | Dementia

Abstract Perivascular spaces (PVSs) facilitate cerebrospinal fluid flow and waste clearance, which are critical for maintaining brain homeostasis. Enlarged PVSs (ePVSs) are an emerging marker of cerebral small vessel disease and are implicated in protein accumulation,...

Outdoor extreme heat‐related dementia risk and the role of socioeconomic disparities: evidence from 20 years of data on US older adults

by Clinical Neuropsychologist Online | Thursday, October 22, 2026 | Dementia

Abstract INTRODUCTION Extreme heat is increasingly recognized as a significant threat to brain health. However, human evidence from large, longitudinal studies remains limited. We examine whether outdoor heat exposure is associated with incident dementia and whether...

Cerebral blood flow as a biomarker of resilience in cognitively unimpaired APOE ɛ4 carriers

by Clinical Neuropsychologist Online | Thursday, October 22, 2026 | Dementia

Abstract INTRODUCTION It remains unclear whether medial temporal lobe (MTL) hyperperfusion in cognitively unimpaired apolipoprotein E (APOE) ɛ4 carriers reflects resilience or dysfunction. We examined whether cortical MTL cerebral blood flow (CBF) relates to cognition...

Biomarker profiles in late‐life depression and Alzheimer’s disease across and beyond the A/T/N framework: A scoping review

by Clinical Neuropsychologist Online | Wednesday, October 21, 2026 | Dementia

Abstract Depression and Alzheimer’s disease (AD) frequently overlap clinically, and depressive symptoms may signal major depressive disorder, a risk factor for AD, or an early manifestation of neurodegeneration. This scoping review mapped biomarker evidence...

Direction‐specific biomarker profiles and clinical significance of plasma p‐tau217/amyloid PET discordance in cognitively normal adults

by Clinical Neuropsychologist Online | Tuesday, October 20, 2026 | Dementia

Abstract INTRODUCTION Plasma phosphorylated tau (p-tau)217 is increasingly used to triage amyloid testing, but the biological and clinical meaning of discordant plasma p-tau217 and amyloid positron emission tomography (PET) results in cognitively normal adults remains...